Folia Neuropathologica
eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2025
vol. 63
 
Share:
Send email
Share:
abstract:
Review paper

Nab-paclitaxel: A revolution in the nano-therapeutic approach to IDH-wildtype glioblastoma

Maria Fareed Siddiqui
1
,
Amber Hassan
2
,
Muzna Tahir
3
,
Fahad Okal
4
,
Saleh Baeesa
5
,
Alaa Alkhotani
6
,
Zayd Jasaniah
7
,
Ahmad Fallatah
8
,
Eyad Faizo
9
,
Dahlia Mirdad
10
,
Bashayer A. Althaqafi
11
,
Maher Kurdi
12

  1. Department of Pharmacy, Faculty of Pharmacy, University of Lahore, Pakistan
  2. European School of Molecular Medicine, University of Milan, Italy
  3. Faculty of Pharmacy, University of Lahore, Pakistan
  4. Department of Neurosurgery, King Abdulaziz Medical City, Jeddah, Saudi Arabia
  5. Department of Neurosciences, King Faisal Specialist Hospital, Jeddah, Saudi Arabia
  6. Department of Pathology, College of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia
  7. Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia
  8. Department of Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia
  9. Department of Surgery, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia
  10. Department of Basic Medical Sciences, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
  11. Department of Neurosurgery, Alnoor Specialist Hospital, Makkah, Saudi Arabia
  12. Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia
Folia Neuropathol 2025; 63 (2): 107-119
DOI: https://doi.org/10.5114/fn.2025.152517
Online publish date: 2025/07/07
View full text Get citation
 
PlumX metrics:
Paclitaxel (PTX) is a potent chemotherapy drug commonly used to treat various solid tumours, including breast and ovarian cancers. However, its effectiveness in treating IDH-wildtype glioblastoma has been limited due to challenges crossing the blood-brain barrier (BBB). Glioblastoma remains one of the most difficult cancers to treat, with a median survival of 15 months from diagnosis. Recent advancements in nanotechnology have led to innovative PTX delivery systems that enhance its bioavailability and enable targeted brain therapy. These include nanoparticles composed of biocompatible materials that enhance drug solubility and targeting while addressing BBB permeability. Examples include albumin-bound PTX (Abraxane), self-assembled nanoparticles from natural bioactive molecules, poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles, and hydrophilic nano-prodrugs, each showing promise in enhancing the therapeutic impact of PTX. These systems utilize biocompatible nanoparticles that enhance drug solubility, targeting, and BBB permeability. Numerous ongoing clinical trials and preclinical studies are exploring the efficacy of these nanocarrier systems in overcoming drug resistance and improving patient outcomes. The latest advancements in PTX-based nanotherapeutics for glioblastoma focus on overcoming the BBB, developing nanoparticle delivery systems, and evaluating the clinical significance of these developments.
keywords:

nab technology, paclitaxel, Abraxane, antimicrotubule agent, apoptosis

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.